Anti-aging Neuropeptides Under research

Pinealon

Also known as: Glu-Asp-Arg, EDR, Péptido bioregulador

Pinealon is a synthetic bioregulator tripeptide (Glu-Asp-Arg) developed within Khavinson's line of "short peptides". It is credited with neuroprotective effects and regulation of gene expression in the central nervous system. It is a research compound within anti-aging medicine.

Mechanism of action

As a bioregulator peptide, it is proposed to act at the epigenetic level.

Gene regulation: it would enter the cell nucleus interacting with DNA sequences and modulating transcription of neuronal genes.
Neuroprotection: reduces oxidative stress and neuronal apoptosis in experimental models.
Note: the mechanism is based mainly on Russian research and animal/cell models.

Uses & indications

Neuroprotection and cognitive support (research).
Brain anti-aging.
Recovery after oxidative stress/hypoxia in experimental models.

Effects

Intended effects: cognitive improvement, neuroprotection and sleep regulation.

Adverse effects: poorly documented in humans; generally well tolerated in available studies. Rigorous clinical trials are lacking.

Considerations & contraindications

Limited clinical evidence, mostly of Russian origin.
Not approved by FDA/EMA.
Quality and purity vary widely between suppliers.

Regulatory approval

Not approved by FDA/EMA. Marketed as a research bioregulator peptide/supplement.

Dosage

In research practice short low-dose cycles have been used. This is not a clinical recommendation.

Storage

Lyophilized: 2–8 °C. Reconstituted: refrigerate and use within a few weeks.

Technical data

Regulatory status Under research

Molecular weight ~388 Da

Half-life Corta (minutos en plasma)

Administration routes Subcutánea, intranasal, oral (investigación)